| Affiliation: | 1. Department of Organizational Systems and Adult Health, University of Maryland, Baltimore, , MD, USA;2. Department of Neurology, Johns Hopkins University School of Medicine, , Baltimore, MD, USA;3. Division of Clinical Oncology‐Department of Medicine, University Hospital of Patras, , Patras, Greece;4. Department of Surgery and Translational Medicine, University of Milan‐Bicocca and Department of Oncology, S. Gerardo Hospital, , Monza, Italy;5. Department of Neurology, Maastricht University Medical Center, Maastricht and Spaarne Hospital, , Hoofdorp, The Netherlands;6. Department of Neurology, VU University Medical Center, , Amsterdam, The Netherlands;7. Clinical Epidemiology and Biostatistic Research Center, Department of Clinical Medicine and Prevention, University of Milano‐Bicocca, , Monza, Italy;8. Unit of Neuro‐Oncology, Department of Neurology, University Hospital of Bellvitge, , L'Hospitalet, Spain;9. Service de Neurologie Mazarin, H?pital Pitié‐Salpêtrière, , Paris, France;10. Service de Neurologie, H?pital du Val‐de‐Grace, , Paris, France;11. Neurology Unit, National Cancer Institute Regina Elena, , Rome, Italy;12. Department of Neurosciences, University of Padova, , Padova, Italy;13. Division of Medical Oncology, Department of Internal Medicine, GROW‐School of Oncology and Developmental Biology, Maastricht University Medical Centre, , Maastricht, The Netherlands;14. Department of Neuro‐oncology, Netherlands Cancer Institute, , Amsterdam, The Netherlands;15. Department of Neurology and West German Cancer Center, University of Essen, , Essen, Germany;16. Edinburgh Centre for Neuro‐Oncology and Edinburgh Cancer Research Centre, Western General Hospital, , Edinburgh, UK;17. Department of Neurosciences, Ophthalmology, Rehabilitation, Genetic and Maternal Infantile Sciences Center of Excellence for Biomedical Research, University of Genova, , Genova, Italy |
| Abstract: | ![]()
Chemotherapy‐induced peripheral neuropathy (CIPN) lacks standardized clinical measurement. The objective of the current secondary analysis was to examine data from the CIPN Outcomes Standardization (CI‐PeriNomS) study for associations between clinical examinations and neurophysiological abnormalities. Logistic regression estimated the strength of associations of vibration, pin, and monofilament examinations with lower limb sensory and motor amplitudes. Examinations were classified as normal (0), moderately abnormal (1), or severely abnormal (2). Among 218 participants, those with class 1 upper extremity (UE) and classes 1 or 2 lower extremity (LE) monofilament abnormality were 2.79 (95% confidence interval [CI]: 1.28–6.07), 3.49 (95%CI: 1.61–7.55), and 4.42 (95%CI: 1.35–14.46) times more likely to have abnormal sural nerve amplitudes, respectively, compared to individuals with normal examinations. Likewise, those with class 2 UE and classes 1 or 2 LE vibration abnormality were 8.65 (95%CI: 1.81–41.42), 2.54 (95%CI: 1.19–5.41), and 7.47 (95%CI: 2.49–22.40) times more likely to have abnormal sural nerve amplitudes, respectively, compared to participants with normal examinations. Abnormalities in vibration and monofilament examinations are associated with abnormal sural nerve amplitudes and are useful in identifying CIPN. |
